Research funder · Australia
Therapeutic Innovation Australia
- Grants since 2016
- 310
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 146
- Funded works, all time
- 282
Grants
2026
Discovery and development of new antimicrobials to combat antibiotic resistance
2026
Assessing efficacy of new generation analgesic nanoparticles for osteoarthritic pain
2026
Novel therapy for cancer
2026
Screen for compounds synthetically lethal with defective RB and p53
2026
Advancing a ‘first-in-class’ monoclonal antibody to combat cancer.
2026
Development of an optimised vaccine formulation to prevent Group A Streptococcus infection
2026
In vivo macrophage modulation
2026
Nanions: a rapid, non-toxic nanoparticle vaccine platform
2026
Novel, small-molecule therapeutics for the treatment of cancers addicted to the oncoprotein Myc
2026
Screening for new treatments for glomerular disease with a new stem cell reporter line
2026
Targeting Pathogenic Genes in Spinocerebellar Ataxia Using Novel Antisense Oligonucleotides
2026
Synthesis and development of targeted degraders of the hepatitis B virus (HBV) core proteins for HBV therapy
2026
Targeting human leishmaniasis
2026
Development and Assessment of Levothyroxine Implant
2026
Regulation of Adenovirus–Protein Interfaces as a Therapeutic Strategy in Thrombosis
2026
Enhancing Therapeutic Efficacy: Pioneering Large-Scale Drug Pipeline Development and Testing on PKU Patients' iPSC-Derived Hepatocytes
2026
Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis
2026
Development of an active immunotherapy for Alzheimer's disease
2026
Efficacy and toxicity measures of a new class of iron chelator
2026
Developing therapeutics that treat/prevent ischemia reperfusion injury (IRI)
2026
Structure-Activity Analysis and Optimisation of Potential MYB-p300 Inhibitors
2026
Process development to optimise and characterise the conjugation process of DFO and monoclonal antibody 10D7
2026
Advancing development of an antibiotic potentiator therapeutic
2026
Accelerated antibiotic discovery through high-throughput
2026
Development and validation of an ECL immunoassay method for quantitation of ustekinumab concentration in human serum
2026
Large-scale production of a TACI-targeting antibody to test its therapeutic efficacy in a preclinical model of chronic lymphocytic leukaemia.
2026
Melanoma Cancer Vaccine Immunotherapy Production & Scaling for Commercialisation
2026
Combatting Schistosomiasis through mRNA-based Transmission blocking vaccines
2026
Development of pan-flaviviral protease inhibitors
2026